Shares of Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) rose 7.6% on Tuesday . The company traded as high as $3.50 and last traded at $3.41, with a volume of 1,275,612 shares trading hands. The stock had previously closed at $3.17.

ANTH has been the subject of a number of analyst reports. HC Wainwright initiated coverage on Anthera Pharmaceuticals in a research note on Friday, July 8th. They set a “buy” rating and a $10.00 price objective for the company. Jefferies Group reissued a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Wednesday, August 10th. FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. Finally, Zacks Investment Research lowered Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $9.58.

The stock has a 50-day moving average price of $3.19 and a 200-day moving average price of $3.40. The stock’s market capitalization is $142.92 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.04. Analysts forecast that Anthera Pharmaceuticals Inc. will post ($1.35) EPS for the current year.

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.